Background/Objectives: Plant sterol (PS) consumption lowers serum cholesterol levels, while modestly increasing plasma PS concentrations. Plasma PS concentrations may reflect sterol absorption, thus individuals with high plasma plant sterol (HPS) concentrations may show greater changes in circulating cholesterol and PS than individuals with low plasma plant sterol (LPS) concentrations. The objective of this study was to examine whether HPS and LPS concentrations are related to subsequent changes in plasma PS, serum lipid and C-reactive protein (CRP) concentrations, following dietary PS intake in otherwise healthy hypercholesterolemic men. Subjects/Methods: This single-blinded, randomized, diet-controlled study consisted of two 4-week phases, separated by a 4-week washout, where a diet with a placebo or the 2.0 g per day PS-enriched spread was consumed during the phases. Results: At baseline, men with HPS possessed higher (Po0.01) mean serum cholesterol concentration, while those with LPS had higher (Po0.05) body mass index. Following PS intake, plasma sum of campesterol plus sitosterol concentrations were elevated from 34.6±4.2 to 46.2±3.3 mmol l À1 (mean±SE) and 16.5±0.9 to 20.8±1.2 mmol l À1 after PS intake in men with HPS and LPS, respectively. Changes in plasma PS concentrations, however, were not different between individuals with either HPS or LPS baseline concentrations. Total cholesterol and low-density lipoprotein cholesterol levels were decreased (Po0.0001) by 6.3 and 7.8%, respectively, with PS consumption for all individuals. Changes in lipid parameters were not different between individuals with HPS or LPS baseline concentrations. No changes in CRP were apparent subsequent to PS intervention. Conclusions: Baseline plasma PS concentrations are not associated or predictive of changes in serum cholesterol or plasma PS concentrations after PS intervention. Thus, individuals with HPS show similar increases in PS concentrations as individuals with LPS following PS supplementation. Plasma PS remained in the range of previously reported concentrations.
Introduction
Hypercholesterolemia is a major yet modifiable risk factor for the development of coronary heart disease (CHD) (Hendriks et al., 1999) . Consumption of plant sterol (PS)-enriched foods reduces cholesterol in a natural effective manner in subjects with modestly elevated serum cholesterol concentrations (Normen et al., 2005) . The intake of 2 g per day of PS reduces low-density lipoprotein cholesterol (LDL-C) by an average of 10% (Katan et al., 2003) . PS and stanols are recommended as therapeutic lifestyle changes to reduce LDL-C (QuIlez et al., 2003) . PS mediate their cholesterol-lowering effect by inhibiting intestinal cholesterol absorption (Moreau et al., 2002) .
In the general population, plasma PS concentrations range from 6.9 to 27.9 mmol l À1 and 2.8 to 16.0 mmol l À1 for campesterol and sitosterol, respectively (Chan et al., 2006) . PS consumption at 2 g per day modestly elevates plasma PS concentrations in hypercholesterolemic individuals (Sudhop and von Bergmann, 2004) . Observational studies suggest that slightly elevated concentrations of PS are associated with an increased risk of cardiovascular events; however, this relationship has not been consistently shown (Glueck et al., 1991; Rajaratnam et al., 2000; Sudhop et al., 2002; Wilund et al., 2004; Miettinen et al., 2005; Assmann et al., 2006; Pinedo et al., 2007) . As plasma PS concentrations may reflect PS absorption efficiency (Matthan and Lichtenstein, 2004; Sudhop and von Bergmann, 2004) there is a need to address whether individuals with high baseline plasma PS (HPS) hyperabsorb PS and show abnormal elevations in plasma levels which are greater than what has previously established.
In addition, earlier studies have raised the possibility that PS may only show beneficial cholesterol-lowering effects in individuals with HPS concentrations (Mussner et al., 2002; Thuluva et al., 2005; Fuentes et al., 2007) . Individuals with higher plasma PS levels may hyperabsorb cholesterol and thus benefit more from an inhibition of intestinal cholesterol absorption. However, these results have to be replicated in the context of a diet-controlled study.
Moreover, PS have been shown to reduce plasma concentrations of the inflammatory markers, interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a) (Bouic, 2001) , tied to C-reactive protein (CRP) levels which affect cardiovascular disease risk. Thus, PS may affect CRP via a reduction in IL-6 and TNF-a; however, data to this effect are limited (Jenkins et al., 2005; AbuMweis et al., 2006; Devaraj et al., 2006) . Therefore, the aims of this study were to determine whether (1) baseline plasma PS concentrations and (2) consumption of PS influence serum total cholesterol (TC) and LDL-C, plasma campesterol and sitosterol, and CRP concentrations in hypercholesterolemic men.
Subject and methods

Subjects
A total of 90 men were recruited by advertisements in local newspapers, clinics and community centers. Inclusion criteria required that participants were between 35 and 70 years of age (25 kg m , with no medical history of diabetes, uncontrolled hypertension or uncontrolled hypothyroidism. Patients taking any cholesterol-lowering medication or PS within the past 6 months were excluded from the study. Of them, 82 participants completed the trial. All study participants gave their written informed consent and the study protocol was approved by the Ethics Committee of the Faculty of Medicine at McGill University. No adverse effects to the treatment margarine were noted over the course of the study.
To effectively recruit a sufficient number of men with HPS and LPS concentrations, a distribution curve for the sum of plasma campesterol plus sitosterol concentrations of the first 40 subjects enrolled into the study was obtained by averaging the first and second screening plasma PS results of each participant. The 25th and 75th percentiles of the distribution curve were determined and defined as the cutoff limits for further screening. Entrance criteria for subsequent recruits required that they either possessed a high (above the 75th percentile) or a low (below the 25th percentile) absolute plasma sum of campesterol plus sitosterol concentrations. Absolute and not cholesterol-standardized PS concentrations were used as the objective of the study was to quantify absolute concentrations in campesterol and sitosterol following PS intake.
Experimental design
During the two 4-week phases of the randomized, singleblinded, diet-controlled trial, subjects only consumed the test diets provided by the metabolic kitchen of the clinical unit. The controlled diet contained 25 g of regular low-fat margarine or the same margarine that provided 2.0 g per day of PS (Unilever Foods, Purfleet, UK) divided into three equal daily portions and provided with meals. The two phases of the study were separated by a 4-week washout period. Diets were equicaloric and followed the guidelines for a Heart Healthy Diet where dietary intake of fat, carbohydrate and protein represented 30, 55 and 15% of energy, respectively. Food and beverages were provided in amounts to maintain a stable body weight using the Mifflin equation (Mifflin et al., 1990) . Body weights continued to be monitored daily throughout the study. Subjects consumed their breakfast each morning at the clinical unit under supervision of the staff. The other two meals were prepared and packed for consumption at work or at home. Subjects were required to consume all provided food and beverage and instructed to refrain from other food and beverage consumption, including coffee and alcohol. Post-treatment PS concentrations served as an indicator of compliance. Fasting blood samples were drawn on days 1, 2, 28 and 29. Blood was then centrifuged at 520 g for 20 min at 4 1C and aliquots were stored at À80 1C.
Analyses
Lipid and C-reactive protein concentrations. Total cholesterol, triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) levels were measured from serum samples using respective reagent Flex on a multianalyzer (Dimension RxL Max, Dade Behring Diagnostics, Marburg, Germany) (Nagele et al., 1984; Esterbauer et al., 1992; Harris et al., 1996) . LDL-C was calculated using Friedewald et al. (1972) equation. Serum CRP was assessed using a highly sensitivity CRP assay (Dade Behring Diagnostics).
Plasma plant sterol concentrations. Plant sterols were extracted as previously described by Wolthers et al. (Jones et al., 2000) . After the addition of the internal standard, 5-a cholestane, 0.3 ml of plasma was saponified and derivatized with TMS reagent (pyridine-hexamethyldisilazan-trimethylchlorosilane (9:3:1, v/v)). Gas chromatographic analysis was used to provide PS peak areas (Lutjohann et al., 1993) . Duplicate samples were injected into a gas chromatograph (Varian 3400, Varian, Palo Alto, CA, USA).
Statistics. Data were analyzed using SAS software (version 9.1, SAS Institute Inc., NC, USA) and expressed in means ± s.e.m. A repeated-measures analysis of variance (ANOVA) design was used to test the main effects of study groups (HPS vs low plasma plant sterol, LPS) and treatments (PS intake vs placebo). HPS and LPS groups were designated using both the 25th and 75th percentiles, as well as the 50th percentile as cutoff points (Figure 1 ). In addition, regression analysis was used to assess whether baseline plasma PS, campesterol and sitosterol concentrations predict changes in serum cholesterol across all individuals. Spearman's correlations were used to test for relations between variables. ShapiroWilks statistics were used to test for normality. Statistical significance was set at Po0.05.
Results
Subject baseline characteristics
The study population consisted of middle-aged, moderately overweight, hypercholesterolemic men (Table 1) . Average circulating concentrations of campesterol, and sitosterol and campesterol plus sitosterol for subjects were 12.8, 6.7 and 19.5 mmol l
À1
, respectively. By design of the study, the HPS group possessed higher (Po0.0001) mean campesterol, sitosterol and sum of PS concentrations compared with levels of the LPS group. The HPS group had higher (Po0.01) mean TC, LDL-C and HDL-C concentrations than the LPS group. The LPS group had a higher (P ¼ 0.041) BMI than the HPS sterol group, but only when data were expressed in terms of the 25th/75th percentile groupings. No differences in baseline TG or CRP concentrations were found between groups. Across all individuals, the sum of baseline PS concentrations was found to correlate with TC (r ¼ 0.44, Po0.0001), LDL-C (r ¼ 0.38, P ¼ 0.0004), HDL-C (r ¼ 0.32, P ¼ 0.0037) and non-HDL-C (r ¼ 0.39, P ¼ 0.0003). No relationship could be established for baseline circulating PS with CRP or TG.
Effect of plant sterol intake on circulating lipid and C-reactive protein concentrations For the total study population, intake of 2.0 g per day of PS reduced (Po0.0001) the post-treatment concentration and the percent change in TC by 0.32 mmol l À1 and 6.3%, respectively, compared to control (Table 2) . For HPS and LPS groups established from the 25th/75th percentiles, absolute Po0.0001 significant from baseline, paired t-test. All data are presented as means ± s.e.m. CRP data were log-transformed before statistical analysis. For post-treatment data, an ANOVA model was used. For percent change data, an ANCOVA model was used with baseline lipid concentrations as covariates. (Table 2) . For HPS and LPS groups established using the 50th percentile, TC levels were reduced by 0.34 and 0.26 mmol l
; percent decreases for these two groups were 7.6 and 5.0 (Figure 2) , respectively compared to control. The effect of group was only significant when baseline concentrations were not controlled for in the ANOVA model (Po0.01).
Across all individuals, LDL-C levels were reduced (Po0.0001) by 0.28 mmol l À1 , or 7.8% compared to control. For HPS and LPS groups established from the 25th/75th percentiles, absolute post-treatment LDL-C concentrations decreased by 0.26 and 0.27 mmol l À1 ; percent decreases for these two groups were 4.6 and 4.9%, respectively, as compared to control. For the high and low PS groups established from the 50th percentile, LDL-C was reduced by 0.30 and 0.25 mmol l
, respectively; decreases amounted to 9.7 and 5.9% (Figure 2 ) for these two groups, respectively, compared to control. The effect of the group was only significant when baseline concentrations were not controlled for in the ANOVA model (Po0.01). Furthermore, while reductions in TC and LDL-C were significantly different between individuals with HPS and LPS, there was no group-by-treatment interaction.
For all subjects, HDL-C concentrations were reduced (Po0.03) by 0.02 mmol l
, compared to control. For the HPS and LPS groups established from the 25th/75th percentiles, HDL-C changed by þ 0.01 and À0.02 mmol l À1 , respectively, compared to control. For HPS and LPS groups established from the 50th percentile, post-treatment HDL-C concentrations decreased by 0.01 and 0.02 mmol l À1 ; percent reductions for these two groups were 2.3 and 3.8 (Figure 2) , respectively, as compared to control. There was no significant interaction between treatment and group. For the study population, TG levels decreased (P ¼ 0.034) by 7.7%, as compared to control. End point TG concentrations following PS intake, however, were not significantly different from TG concentrations following consumption of the control diet. Additionally, no differences were observed in percent change of TG concentrations between HPS and LPS individuals (Figure 2) . No significant association was noted for baseline circulating PS concentrations and CRP.
Effect of plant sterol intake on circulating plasma sterol concentrations For all individuals, plasma campesterol concentrations were elevated (Po0.0001) by 24.3% or 3.7 mmol l À1 following intake of 2.0 g per day of PS (Table 3) . Mean campesterol concentration after PS intervention was 19.8 mmol l
. For HPS and LPS groups established from the 25th/75th percentiles, the absolute post-treatment concentrations of campesterol increased by 31.9 and 49.1%, respectively, as compared to control. For HPS and LPS groups established from the 50th percentile, the absolute post-treatment campesterol concentrations increased by 13.8 and 34.9% (Figure 3) , respectively, as compared to control. Although elevations in campesterol were significantly different between individuals with HPS and LPS, there was no group by treatment interaction.
Across all study participants, sitosterol concentrations increased (Po0.0001) by 28.2%. For HPS and LPS groups established from the 25th/75th percentiles, post-treatment concentrations of sitosterol increased by 51.8 and 46.0%, respectively, as compared to control. For HPS and LPS groups established from the 50th percentile, post-treatment sitosterol concentrations increased by 28.8 and 27.6% (Figure 3) , respectively, as compared to control.
Across all study participants, lathosterol and desmosterol concentrations were not changed following PS supplementation, as compared to control. There were no significant interactions observed between group and treatment for either lathosterol or desmosterol.
Associations between variables
No significant relationships were observed between baseline campesterol plus sitosterol concentrations and the percent change in TC and LDL-C levels following PS intake across all study participants, as compared to control (r adj ¼ À0.059, P ¼ 0.399; r adj ¼ 0.109, P ¼ 0.811, for TC and LDL-C, respectively). Similarly, no significant relationship was apparent when baseline campesterol plus sitosterol concentrations were plotted against end of PS phase serum cholesterol values across all individuals, as compared to control (r adj ¼ À0.130, P ¼ 0.722; r adj ¼ 0.151, P ¼ 0.150, for TC and LDL-C, respectively) (Figure 4) . All data are presented as means±s.e.m. For post-treatment data, the ANOVA model was used. For percent change data, the ANCOVA model was used with baseline sterol levels as covariates.
For PS levels, baseline campesterol plus sitosterol concentrations did not correlate with percent changes in campesterol and sitosterol following PS intake across all study participants, compared to control (r adj ¼ À0.10, P ¼ 0.69; r adj ¼ À0.11, P ¼ 0.86, for campesterol and sitosterol, respectively). Similarly, no correlation was apparent when baseline sum of PS concentrations were plotted against the absolute post-PS treatment campesterol and sitosterol concentrations for all individuals, as compared to control (r adj ¼ À0.08, P ¼ 0.48; r adj ¼ À0.13, P ¼ 0.73, for campesterol and sitosterol, respectively; Figure 5 ).
Discussion
This study demonstrates that the sum of baseline circulating PS concentrations does not predict or associate with elevations in plasma PS, following a dietary intake of 2.0 g per day of PS in a hypercholesterolemic, but otherwise healthy population. Although elevations in circulating PS concentrations were highly variable between individuals, changes occurred independently of the sum of baseline circulating PS concentrations. Thus, individuals with naturally HPS levels show no difference in their increases in plasma PS levels compared with their LPS counterparts following PS supplementation.
Baseline circulating PS concentrations were, however, related to the baseline cholesterol concentrations (TC, LDL-C and HDL-C) and the BMI. Gylling et al. (2004) have demonstrated that HPS and LPS individuals, established from cholestanol to cholesterol ratios, have different average BMI; however, their groups did not differ in terms of their TC, LDL-C and HDL-C concentrations. The contradictory data obtained from these studies may be attributed to a difference in genetic background of the populations under investigation. The apoE and ABCG5/G8 genes that influence cholesterol absorption and BMI are thought to account for 16.4-22.7% of the variation in plasma PS concentrations (Chan et al., 2006) . In opposition, the present study compared lipid concentrations of HPS and LPS groups established from the absolute PS levels of study participants; thus it is possible that a difference in BMI between HPS and LPS groups would have been noted if groups had been established using PS ratios, as demonstrated in a recent study by Pinedo et al. (2007) . Mean baseline campesterol and sitosterol concentrations reported here fall within the range of concentrations established in a recent review by Chan et al. (2006) .
Excessively elevated concentrations of plasma PS are associated with the rare lethal autosomal-recessive disorder, sitosterolemia (Sudhop and von Bergmann, 2004) . Since elevations in plasma PS concentrations following PS interventions are not comparable to the 290-966 mmol l À1 concentrations manifest in sitosterolemic individuals, PS intake should be viewed as safe (Sudhop and von Bergmann, 2004) . In a crossover trial supplementation with 1.8 g per day of PS to 63 healthy individuals elevated plasma campesterol plus sitosterol concentrations from 9.0 to 16.6 mmol l À1 and 4.4 to 6.0 mmol l À1 (Mussner et al., 2002) . Clifton et al. (2004) showed that supplementation with a larger dose of 6.6 g per day in 35 mildly hypercholesterolemic subjects increased campesterol and sitosterol concentrations to a similar extent (7.8-15.8 and 8.0-11.4 mmol l À1 , respectively). No studies thus far, however, have considered the extent to which PS intake elevates concentrations of plasma campesterol and sitosterol as a function of natural circulating levels as was done presently. However, PS use may be perceived as less favorable for HPS individuals since they may have higher intestinal PS absorption efficiencies. Results from this study, however, demonstrate that HPS individuals, despite having endogenously high PS levels, do not show greater elevations in circulating PS concentrations after PS treatment.
Certain studies suggest that moderately elevated plasma PS concentrations are associated with a greater CHD risk (Glueck et al., 1991; Rajaratnam et al., 2000; Sudhop et al., 2002; Miettinen et al., 2005; Assmann et al., 2006) . Glueck et al. (1991) suggested a relationship between campesterol, but not sitosterol, concentrations and CHD risk in a study of 565 hypercholesterolemic patients. Contrarily, Assmann et al. (2006) found that sitosterol, but not campesterol, concentrations were elevated in cases with myocardial infarction or major coronary events compared to age-and smoking status-matched controls. Although Assmann et al. (2006) and Glueck et al. (1991) both concluded that plasma PS are associated with CHD risk, the relationship was not established independently from serum cholesterol, which on its own is a major risk factor for CHD. Accordingly, these studies cannot be used together as supporting evidence that CHD risk is associated with moderately elevated plasma PS concentrations. Other data (Rajaratnam et al., 2000; Sudhop et al., 2002; Miettinen et al., 2005) do reinforce an association between plasma PS and CHD risk for both campesterol and sitosterol. Nevertheless, the proportion of cholesterol to PS concentrations in serum and plaque tissue and the ratio PS/cholesterol remained the same, suggesting no preferential uptake of PS into plaque tissue and thus no accelerated accumulation.
Three more recent reports refute earlier evidence that moderately elevated plasma PS concentrations associate with an increased risk of CHD. Wilund et al. (2004) demonstrated that plasma PS concentrations do not differ between individuals with a positive history of heart disease and case-matched controls. Baseline plasma PS concentrations did not associate with atherosclerosis based on arterial calcium scores, a marker of the degree of atherosclerosis. Pinedo et al. (2007) also demonstrated that baseline plasma PS concentrations were not different among healthy individuals who developed CHD during a 6-year follow-up and case-matched controls. Another recent study suggests that baseline plasma PS concentrations could potentially have a protective effect on the development of CHD (Fassbender et al., 2006) .
Baseline plasma PS concentrations were further examined in the context of their role in the cholesterol-lowering response to PS intake. Contrary to findings by Mussner et al. (2002) , Thuluva et al. (2005) and Fuentes et al. (2007) , the present study results demonstrate that baseline PS are not predictive of changes in TC and LDL-C, following PS supplementation. None of the above-mentioned studies observed associations between baseline plasma PS concentrations and the cholesterol-lowering response. Furthermore, the linear relationship established in the trial by Thuluva et al. (2005) may have been confounded by data clustering, as only HPS and LPS individuals were included in the regression analysis. Miettinen and Gylling (2002) indicated that individuals with HPS concentrations show a greater cholesterol-lowering response than their LPS counterparts. Results from that trial cannot be directly compared to those of the current study as this effect was noted in a patient population following simvastatin treatment (Miettinen and Gylling, 2002) . Overall, differences in experimental design and methodology employed render it difficult to make comparisons across studies. Ultimately, the relationship between baseline plasma PS concentrations and cholesterol absorption efficiency would have most accurately been captured with direct measuring cholesterol absorption with isotopic techniques.
To summarize, the present data demonstrate that baseline plasma PS concentrations are not associated with, or predictive of, changes in plasma PS, cholesterol or CRP concentrations following PS supplementation. Additionally, elevations in plasma PS concentrations as found in this study remained far below values expressed in sitosterolemic patients. In view of these data, a supplement of 2.0 g per day of PS should be viewed as a beneficial cholesterol-lowering therapy that modestly elevates circulating PS concentrations to the same extent across all individuals, irrespective of their baseline plasma PS concentrations.
